Thu, Sep 18, 2014, 6:38 AM EDT - U.S. Markets open in 2 hrs 52 mins


% | $
Quotes you view appear here for quick access.

Theratechnologies Inc. Message Board

  • kgus79 kgus79 Oct 1, 2010 4:18 AM Flag

    Bad News?

    The last few paragraphs of this article have me concerned. Comments?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Scratch that link....basically the last few paragraphs were as follows:

      Cautious Appraisal of the Growth-Hormone Analog in HIV-Positive Patients

      "This drug has not been approved by the FDA yet," said Jens Lundgren, MD, from the University of Copenhagen HIV Programme in Denmark.

      "It may be that tesamorelin adversely affects other metabolic parameters, which is a concern. Are the cosmetic effects worth the side effects? The FDA will decide that," he noted.

      In Dr. Lundgren's opinion, even if tesamorelin is approved, it will not be used that often. "As soon as the drug is stopped, the fat comes back, so treatment would have to be lifelong," he explained. Patients with VAT could try diet and exercise for their bellies, he added.

      Tesamorelin might find a role as a treatment for the few patients with pathologic interabdominal fat that interferes with respiration, Dr. Lundgren continued. "If there is a niche for this drug, this might be it," he stated.

      In addition, this was stated in the middle of the article....

      Tesamorelin is an investigative analog of growth-hormone-releasing factor and growth-hormone-releasing hormone. The drug is pending approval by the US Food and Drug Administration (FDA), but some investigators are not enthusiastic about using it, except perhaps for specific indications.

0.59+0.01(+1.72%)Sep 17 3:58 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.